Acute-on-Chronic Liver Failure (ACLF) is a syndrome in cirrhosis that is characterized by acute decompensation (AD), organ failure(s), and high short-term mortality.
As per Delveinsight, in 2017, the total population of Acute-on-Chronic Liver Failure (ACLF) in 7MM was 60,521. The population of ACLF cases in the United States was found to be 12,577.
The Acute-on-Chronic Liver Failure (ACLF) therapeutic market in 7MM [i.e. the United States, EU5 (Spain, Germany, Italy, France, and the UK) and Japan] was USD 70.55 million in 2017.
The absence of curative and disease-specific treatment options, innovative therapeutic approaches, and progress in the understanding of the disease are some of the key drivers for the Acute on Chronic Liver Failure market.
Some of the key companies in the Acute on Chronic Liver Failure market include RHEACELL, Versantis, Martin Pharmaceuticals, and many others.
For more details, visit: Acute On Chronic Liver Failure (ACLF) Market Growth